Drug Development Pipeline
Restore CFTR Protein
This program aimed to expand the number of therapies designed to fix the defective CFTR protein in people who have the F508del mutation.
No further development in CF is planned at this time.
This program was sponsored by Reata Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
